MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.190
+0.020 (1.71%)
Oct 2, 2026, 4:00 PM EDT - Market closed
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,065,015
Market Cap
72.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Verrica Pharmaceuticals | 76 |
| Spero Therapeutics | 25 |
| iBio, Inc. | 23 |
| Gain Therapeutics | 21 |
| RenovoRx | 17 |
| Cingulate | 14 |
| Rein Therapeutics | 10 |
MAIA News
- 3 days ago - Diamond Equity releases update note on MAIA Biotechnology - TheFly
- 3 days ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 8 days ago - MAIA Biotechnology files to sell 751,879 shares of common stock for holders - TheFly
- 9 days ago - MAIA Biotechnology Registration statement: Registration filing - Filings
- 11 days ago - MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal - GlobeNewsWire
- 12 days ago - MAIA Biotechnology reports Phase 3 trial progress in advanced NSCLC - TheFly
- 12 days ago - MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer - GlobeNewsWire
- 18 days ago - MAIA Biotechnology doses first U.S. patient in THIO-101 trial expansion - TheFly